Browsing by Author
Oya, M.
Showing results 1 to 3 of 3
| Issue Date | Title | Author(s) |
| 2022 | Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) | Saad, F.; Armstrong, A. J.; Thiery-Vuillemin, A.; Oya, M.; Shore, N. D.; Procopio, G.; Arslan, C. |
| 2023 | Efficacy of olaparib (ola) plus abiraterone (abi) vs placebo (pbo) plus abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial | Mehra, N.; Clarke, N. W.; Armstrong, A. J.; Oya, M.; Shore, N. D.; Procopio, G.; Guedes, J. D. C.; Arslan, Çağatay |
| 2023 | Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial | Saad, F.; Clarke, N.W.; Oya, M.; Shore, N.; Procopio, G.; Guedes, J.D.; Arslan, Çağatay |
